Good evening :)
Place Order
Add to Watchlist

Gujarat Themis Biosyn Ltd

GUJTHEM

Gujarat Themis Biosyn Ltd

GUJTHEM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,794 cr, stock is ranked 884
High RiskStock is 4.92x as volatile as Nifty
384.750.03% (+0.10)
384.750.03% (+0.10)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,794 cr, stock is ranked 884
High RiskStock is 4.92x as volatile as Nifty
Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,794 cr, stock is ranked 884
High RiskStock is 4.92x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
50.8418.740.28%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.555.890.57%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The company makes bulk drugs. It's R&D division focuses on developing fermentation cultures. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 31.8%, vs industry avg of 8.36%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.02% to 0.05%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 71.82%, vs industry avg of 9.82%

Loading...

Financial YearFY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023TTM
Total Revenue31.5532.7936.0538.9743.2686.8293.83118.90154.99160.74
Raw Materialssubtract0.290.321.492.151.3015.4415.7521.7529.7383.27
Power & Fuel Costsubtract16.1617.1517.9919.3320.2022.8616.5721.7326.41
Employee Costsubtract4.004.284.424.465.176.437.117.087.75
Selling & Administrative Expensessubtract0.950.940.851.101.391.641.862.316.66
Operating & Other expensessubtract3.793.904.905.525.626.918.943.944.20
Depreciation/Amortizationsubtract1.381.201.121.151.221.361.732.232.583.38
Interest & Other Itemssubtract0.390.380.410.420.160.920.980.830.200.18
Taxes & Other Itemssubtract0.000.000.500.971.797.5910.7115.4119.5018.95
EPS0.630.640.600.530.883.264.156.007.987.57
DPS0.000.000.000.000.000.330.002.201.080.20
Payout ratio0.000.000.000.000.000.100.000.370.140.03

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Nov 15PDF
Nov 15PDF
Sep 13PDF
Sep 13PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Gujarat Themis Biosyn Ltd48.2118.740.28%
Sun Pharmaceutical Industries Ltd43.616.230.75%
Cipla Ltd39.804.700.62%
Dr Reddy's Laboratories Ltd22.214.300.67%

Price Comparison

Compare GUJTHEM with any stock or ETF
Compare GUJTHEM with any stock or ETF
GUJTHEM
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 4.13%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.66%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding70.86%0.02%0.02%0.87%28.23%

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Shareholding History

SepDec '22MarJunSepDec '230.00%0.01%0.01%0.01%0.01%0.87%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 2 Mutual Funds holding Gujarat Themis Biosyn Ltd



Funds (Top 2)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
quant Healthcare Fund - Growth - Direct Plan

Growth
0.4607%4.87%4.87%11/27 (+8)
quant Manufacturing Fund - Growth Option - Direct Plan

Growth
0.3473%1.77%1.77%38/41 (+2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateFeb 22, 2024

Interim
Interim | Div/Share: ₹0.75

Dividend/Share

0.75

Ex DateEx Date

Feb 22, 2024

Cash Dividend

Ex DateEx DateSep 1, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 1, 2023

Cash Dividend

Ex DateEx DateDec 1, 2022

Interim
Interim | Div/Share: ₹4.40

Dividend/Share

4.40

Ex DateEx Date

Dec 1, 2022

Cash Dividend

Ex DateEx DateAug 29, 2022

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Aug 29, 2022

Cash Dividend

Ex DateEx DateNov 24, 2021

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Nov 24, 2021

News & Opinions

Hmm, looks like data is unavailable here. Please come back after some time.